HER2+ breast cancer- Cracking the code of exceptional response to improve outcomes.
About the Project
Commencement date
September 2026
Location
Cancer Biotherapeutics Research Group, Life Sciences Institute, Dublin City University, Dublin, Ireland
Project overview
We are seeking a highly motivated PhD candidate to join an ambitious translational cancer research project aiming to transform outcomes for patients with HER2-positive (HER2+) breast cancer.
HER2+ breast cancer accounts for approximately 20% of all breast cancer cases and remains a major clinical challenge, particularly in advanced disease. While most patients with metastatic HER2+ cancer have a median survival of less than five years, a remarkable subset—known as exceptional responders—survive for over a decade, and sometimes up to 20 years [1].
This PhD project will investigate the biological mechanisms underlying these extraordinary responses, with the goal of translating these insights into improved diagnostics, therapeutic strategies, and personalised treatment approaches. It is a cross-disciplinary project that will require the student to generate and analyse large datasets and also carry out in vitro validation of identified targets.
Find Your Best Opportunity
Tell them AcademicJobs.com sent you!
